医学
挽救疗法
化疗
淋巴瘤
肿瘤科
弥漫性大B细胞淋巴瘤
癌症
内科学
作者
Laurie H. Sehn,Gilles Salles
标识
DOI:10.1056/nejmra2027612
摘要
DLBCL, an aggressive cancer, accounts for about 30% of all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially, with another 20 to 25% cured with salvage therapy. Efforts are ongoing to tailor therapy to particular genetic lesions.
科研通智能强力驱动
Strongly Powered by AbleSci AI